Chronic Lymphocytic Leukemia

Harry Paul Erba, MD, PhD, discusses selecting between ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

The FDA has granted an orphan drug designation to LAVA-051, a CD1d-targeted Gammabody, for the treatment of patients with chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia and other hematologic malignancies.

Farrukh Awan shares a case of a patient with a cardiac history recently diagnosed with CLL requiring treatment.

Two experts discuss strategies for managing atrial fibrillation in patients with CLL on BTKi therapy.

Alexey V. Danilov, MD, PhD, discusses the rationale to combine entospletinib with obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Alexey Danilov, MD, PhD, discussed the data on entospletinib/obinutuzumab in patients with R/R CLL and suggests further research directions with this drug combination.

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, review the risk versus benefit of anticoagulation strategies in patients on BTKi.

Drs Lenneman and Awan discuss baseline testing before choosing a treatment strategy for battling chronic lymphocytic leukemia.

Two experts discuss key safety considerations when treating patients with chronic lymphocytic leukemia.

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, give an overview of chronic lymphocytic leukemia, the standard of care for treatment, and the current and emerging BTK inhibitors used to treat CLL.

Tadeusz Robak, MD, discussed the 7-year safety and efficacy data from the RESONATE-2 trial examining frontline ibrutinib in CLL.

The frontline triplet combination comprised of acalabrutinib, venetoclax, and obinutuzumab proved to be highly active and well tolerated when used in the treatment of patients with chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.

Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia.

Meghan Thompson, MD, discusses the results of the phase 1/2 BRUIN study in patients with Richter transformation.

Tadeusz Robak, MD, PhD, discusses the results of the 7-year follow-up analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

During the XIX International Workshop on Chronic Lymphocytic Leukemia, which occurred virtually 17-20 September, Dr. John Byrd was presented the Binet-Rai Medal Award for his outstanding findings, which led to the use of BTK Inhibitors in almost every phase of CLL therapy.

The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.

William G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the results of a first-in-human, early phase 1 study of lisaftoclax in patients with hematologic malignancies.

A genome-wide look into changes in three-dimensional chromatin organization between ibrutinib-resistant and parental chronic lymphocytic leukemia cells illustrated the involvement of PAK1 as an oncogenic driver in CLL.

Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.

Chan Cheah, MBBS, discusses the results of a study evaluating the efficacy and safety of TG-1701 alone and in combination with ublituximab and umbralisib in chronic lymphocytic leukemia.

Alexey V. Danilov, MD, PhD, discusses the efficacy of entospletinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.